DelveInsight Releases Report on Tendinopathy Treatment Pipeline Development

Market research firm DelveInsight has published its "Tendinopathy - Pipeline Insight, 2026" report, offering a comprehensive overview of the current state and future potential of drug development initiatives targeting tendinopathy.

The report covers over five companies and more than five pipeline drugs in development for tendinopathy. It includes profiles of drug candidates in both clinical and non-clinical stages, assessing them by factors such as product type, stage, route of administration, and molecule type. The report also highlights inactive pipeline products.

Tendinopathy is a common musculoskeletal condition characterized by pain, impaired function, and structural changes within tendons. It is frequently associated with overuse, repetitive strain, or acute injury, leading to symptoms like localized pain, tenderness, swelling, and restricted movement that can significantly impact quality of life.

Emerging therapies are exploring novel approaches to treatment. One such example is Causeway Therapeutics' TenoMiR (CWT-001), a microRNA replacement therapy currently in Phase II clinical trials for tendinopathy patients. The treatment aims to restore normal tendon structure and function by targeting critical disease pathways.